Coxsackie virus A16 type mouse-adapted strain and application thereof
A technology of Coxsackie virus and mouse-adapted strains, which is applied in the fields of virology and molecular biology, and can solve problems such as safety and effectiveness evaluation methods
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0020] Isolation, cultivation and identification of embodiment 1CA16 virus strain
[0021] (1) Virus isolation and culture
[0022] The fecal samples of patients with positive CA16 virus PCR results were collected from the HFMD epidemic area in Zhejiang Province in 2010 (the cumulative number of HFMD cases reached 111,783). After treatment, they were inoculated onto African green monkey kidney passage cells (Vero), and cultured for three generations for virus isolation. , to obtain the CA16 virus strain.
[0023] (2) Virus identification
[0024] 1. RT-PCR detection
[0025] The CA16 genomic RNA of the strain was extracted, reverse-transcribed into cDNA, and identified using VP1 conserved region primers (upstream primer: 5'-TTGCAGACATGATTGACCAG-3', downstream primer: 5'-GAGTGATGGTTCAACACACA-3'). The results showed that There was a single band at 212bp in the isolated strain ( figure 1 ), it can be proved that the strain isolated from clinical specimens is CA16 virus.
[0...
Embodiment 2CA16
[0030] Preparation of embodiment 2CA16 mouse-adapted strain
[0031] Virus liquid: Infect RD cells with the above-mentioned CA16 virus strain, harvest the virus liquid after 7 days, freeze and thaw three times, and centrifuge to take the supernatant virus liquid for later use.
[0032] Animals: Purchase clean grade BALB / c pregnant mice, provide sufficient food and drinking water, clean the cage and replace the bedding every week.
[0033] Preparation and library construction of CA16 mouse-adapted strain: Inoculate the prepared CA16 virus solution into the brain of suckling mice after birth, with an inoculation volume of 30 μL / mouse (the virus titer is 6.12lg CCID50 / mL), and set normal suckling mice at the same time. control. The status of suckling mice was observed every day after virus inoculation. The brain tissue of the sick mice was collected and homogenized, and after centrifugation, the adapted strains were obtained by continuing passage for 4 times according to the ab...
Embodiment 3CA16
[0038] Application of embodiment 3CA16 mouse adaptation strain
[0039] Dilute the calibrated mouse-adapted strain to 20LD50 / 0.1mL, mix it with CA16 virus-immune sheep serum and human CA16 virus-infected convalescent serum at 37°C, after neutralization, inject 5-day-old suckling mice for preliminary evaluation of CA16 virus Protective effect of sera after immunization and human sera after natural infection. The results are shown in Table 1:
[0040] Table 1 Results of antivirus protection
[0041]
[0042] The results showed that the prepared mouse-adapted strain could effectively evaluate the protection of CA16 virus immune sera and naturally infected CA16 human sera. It can further lay the foundation for the study of Coxsackie A16 etiology, pathogenesis, screening of high-efficiency drugs and development of vaccines.
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 